Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Common Equity (2020 - 2025)

Journey Medical's Common Equity history spans 6 years, with the latest figure at $31.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 58.71% year-over-year to $31.9 million, compared with a TTM value of $31.9 million through Dec 2025, up 58.71%, and an annual FY2025 reading of $31.9 million, up 58.71% over the prior year.
  • Common Equity for Q4 2025 was $31.9 million at Journey Medical, up from $25.9 million in the prior quarter.
  • The five-year high for Common Equity was $42.0 million in Q4 2021, with the low at -$11.7 million in Q3 2021.
  • Average Common Equity over 5 years is $17.9 million, with a median of $18.3 million recorded in 2023.
  • Year-over-year, Common Equity crashed 271.61% in 2021 and then surged 225800.0% in 2024.
  • Tracing DERM's Common Equity over 5 years: stood at $42.0 million in 2021, then crashed by 59.61% to $17.0 million in 2022, then increased by 19.83% to $20.3 million in 2023, then decreased by 1.38% to $20.1 million in 2024, then surged by 58.71% to $31.9 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Common Equity are $31.9 million (Q4 2025), $25.9 million (Q3 2025), and $19.2 million (Q2 2025).